Univariable association between predictor variables and major bleeding during follow-up
| Variable . | Patients with major bleed (n = 118) . | Patients without major bleed (n = 2398) . | Hazard ratio (95% CI) . | Missing values . |
|---|---|---|---|---|
| Median age, y | 69 (57-76) | 61 (49-71) | 1.03 (1.02-1.05)* | 0 |
| Female sex | 58 (49) | 849 (35) | 1.81 (1.25-2.60) | 0 |
| Race | 5 (0.2) | |||
| White | 104 (88.1) | 2201 (92.0) | Ref. | |
| Black | 12 (10.2) | 155 (6.5) | 1.75 (0.96-3.19) | |
| Other | 2 (1.7) | 37 (1.5) | 1.34 (0.33-5.37) | |
| Prior myocardial infarction | 7 (5.9) | 119 (5.0) | 1.24 (0.58-2.66) | 0 |
| Prior gastrointestinal bleed | 4 (3.4) | 79 (3.3) | 1.16 (0.43-3.13) | 0 |
| Hypertension | 61 (51.7) | 887 (37.0) | 1.73 (1.20-2.49) | 0 |
| Diabetes | 17 (14.4) | 256 (10.7) | 1.45 (0.87-2.42) | 0 |
| Obesity | 61 (51.7) | 1149 (48.0) | 1.07 (0.75-1.55) | 5 (0.2) |
| Postthrombotic syndrome | 16 (14.0) | 491 (21.1) | 0.69 (0.40-1.19) | 73 (2.9) |
| Smoking | 8 (6.8) | 274 (11.4) | 0.57 (0.28-1.17) | 1 (<0.1) |
| Antiplatelet agent | 18 (15.2) | 129 (5.4) | 2.99 (1.80-4.96) | 0 |
| Statin | 48 (41.0) | 635 (26.5) | 1.99 (1.37-2.88) | 2 (0.1) |
| Exogenous estrogen | 48 (41.0) | 651 (27.2) | 1.92 (1.32-2.78) | 2 (0.1) |
| Selective serotonin reuptake inhibitor | 10 (8.5) | 129 (5.4) | 1.66 (0.87-3.16) | 0 |
| Hypercholesterolemia | 35 (36.5) | 660 (33.9) | 1.15 (0.76-1.75) | 475 (19) |
| Median creatinine, µmol/L | 85 (68-105) | 80 (69-94) | 1.002 (1.001-1.004)* | 174 (6.9) |
| Median hemoglobin, g/L | 138 (122-147) | 143 (133-152) | 1.02 (1.01-1.02)† | 37 (1.5) |
| Anemia, % | 34 (28.8) | 283 (12.0) | 3.19 (2.13-4.76) | 37 (1.5) |
| Prothrombin gene mutation or Factor V Leiden | 19 (46.3) | 345 (43.3) | 1.23 (0.66-2.28) | 1677 (67) |
| Antiphospholipid antibodies | 11 (22.9) | 176 (20.6) | 1.12 (0.57-2.21) | 1615 (64) |
| Protein C or S deficiency | 6 (14.3) | 117 (14.9) | 0.88 (0.37-2.06) | 1688 (67) |
| Antithrombin deficiency | 1 (2.1) | 28 (3.0) | 0.72 (0.10-5.21) | 1534 (61) |
| CYP2C93(T/G) | 21 (19.8) | 223 (10.4) | 2.03 (1.26-3.29) | 257 (10) |
| Variable . | Patients with major bleed (n = 118) . | Patients without major bleed (n = 2398) . | Hazard ratio (95% CI) . | Missing values . |
|---|---|---|---|---|
| Median age, y | 69 (57-76) | 61 (49-71) | 1.03 (1.02-1.05)* | 0 |
| Female sex | 58 (49) | 849 (35) | 1.81 (1.25-2.60) | 0 |
| Race | 5 (0.2) | |||
| White | 104 (88.1) | 2201 (92.0) | Ref. | |
| Black | 12 (10.2) | 155 (6.5) | 1.75 (0.96-3.19) | |
| Other | 2 (1.7) | 37 (1.5) | 1.34 (0.33-5.37) | |
| Prior myocardial infarction | 7 (5.9) | 119 (5.0) | 1.24 (0.58-2.66) | 0 |
| Prior gastrointestinal bleed | 4 (3.4) | 79 (3.3) | 1.16 (0.43-3.13) | 0 |
| Hypertension | 61 (51.7) | 887 (37.0) | 1.73 (1.20-2.49) | 0 |
| Diabetes | 17 (14.4) | 256 (10.7) | 1.45 (0.87-2.42) | 0 |
| Obesity | 61 (51.7) | 1149 (48.0) | 1.07 (0.75-1.55) | 5 (0.2) |
| Postthrombotic syndrome | 16 (14.0) | 491 (21.1) | 0.69 (0.40-1.19) | 73 (2.9) |
| Smoking | 8 (6.8) | 274 (11.4) | 0.57 (0.28-1.17) | 1 (<0.1) |
| Antiplatelet agent | 18 (15.2) | 129 (5.4) | 2.99 (1.80-4.96) | 0 |
| Statin | 48 (41.0) | 635 (26.5) | 1.99 (1.37-2.88) | 2 (0.1) |
| Exogenous estrogen | 48 (41.0) | 651 (27.2) | 1.92 (1.32-2.78) | 2 (0.1) |
| Selective serotonin reuptake inhibitor | 10 (8.5) | 129 (5.4) | 1.66 (0.87-3.16) | 0 |
| Hypercholesterolemia | 35 (36.5) | 660 (33.9) | 1.15 (0.76-1.75) | 475 (19) |
| Median creatinine, µmol/L | 85 (68-105) | 80 (69-94) | 1.002 (1.001-1.004)* | 174 (6.9) |
| Median hemoglobin, g/L | 138 (122-147) | 143 (133-152) | 1.02 (1.01-1.02)† | 37 (1.5) |
| Anemia, % | 34 (28.8) | 283 (12.0) | 3.19 (2.13-4.76) | 37 (1.5) |
| Prothrombin gene mutation or Factor V Leiden | 19 (46.3) | 345 (43.3) | 1.23 (0.66-2.28) | 1677 (67) |
| Antiphospholipid antibodies | 11 (22.9) | 176 (20.6) | 1.12 (0.57-2.21) | 1615 (64) |
| Protein C or S deficiency | 6 (14.3) | 117 (14.9) | 0.88 (0.37-2.06) | 1688 (67) |
| Antithrombin deficiency | 1 (2.1) | 28 (3.0) | 0.72 (0.10-5.21) | 1534 (61) |
| CYP2C93(T/G) | 21 (19.8) | 223 (10.4) | 2.03 (1.26-3.29) | 257 (10) |